Valuation: Evolus, Inc.

Market Cap 475M 431M 398M 359M 677M 44.81B 701M 4.79B 1.9B 23.94B 1.78B 1.75B 75.98B P/E 2026 *
-14x
P/E 2027 * -44.9x
Enterprise Value 590M 535M 495M 446M 841M 55.65B 871M 5.94B 2.36B 29.73B 2.21B 2.17B 94.37B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.53x
Free-Float
85.06%
Yield 2026 *
-
Yield 2027 * -
1 day-2.02%
1 week+3.82%
Current month-3.88%
1 month-5.93%
3 months-11.91%
6 months+5.13%
Current year+6.24%
1 week 6.63
Extreme 6.63
7.65
1 month 6.41
Extreme 6.412
7.83
Current year 3.86
Extreme 3.86
9.31
1 year 3.86
Extreme 3.86
9.31
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Chief Executive Officer

-105,108 0.1625%
20/03/26 Sell

Chief Executive Officer

13,669 0.0211%
20/03/26 Sell

Chief Technology Officer

3,119 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%+3.82%-4.14%-12.99% 475M
+1.50%+6.92%+41.53%+136.27% 1,271B
+1.00%+3.60%+46.56%+93.84% 683B
+0.35%+1.42%+27.19%+113.11% 520B
-0.44%+3.69%+39.60%+69.51% 389B
+0.24%+0.35%+58.44%+43.69% 362B
-0.12%+0.74%+26.78%+58.43% 304B
+0.37%+0.37%+3.62%+36.44% 286B
-0.30%+1.10%+38.53%+74.54% 253B
+0.19%+0.78%+34.35%+124.48% 208B
Average +0.09%+2.13%+31.25%+73.73% 428B
Weighted average by Cap. +0.63%+2.67%+37.73%+96.32%

Financials

2026 *2027 *
Net sales 334M 303M 280M 253M 476M 31.52B 493M 3.37B 1.33B 16.84B 1.25B 1.23B 53.44B 391M 354M 327M 295M 557M 36.83B 576M 3.93B 1.56B 19.67B 1.47B 1.43B 62.45B
Net income -33.9M -30.72M -28.41M -25.63M -48.31M -3.2B -50.01M -341M -135M -1.71B -127M -125M -5.42B -10.23M -9.27M -8.58M -7.74M -14.58M -965M -15.1M -103M -40.85M -515M -38.4M -37.59M -1.64B
Net Debt 115M 104M 96.39M 86.97M 164M 10.84B 170M 1.16B 459M 5.79B 432M 422M 18.39B 121M 110M 101M 91.51M 172M 11.41B 179M 1.22B 483M 6.09B 454M 444M 19.35B
Projected Income Statement - Annual - Evolus, Inc.
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
365
Date Price Change Volume
13/11/26 $7.100 -1.11% 244,894
12/11/26 $7.180 -3.23% 737,093
11/11/26 $7.420 +8.96% 1,287,323
10/11/26 $6.810 -2.44% 5,816,222
09/11/26 $6.980 +2.57% 1,150,209
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Evolus, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.180USD
Average target price
15.40USD
Spread / Average Target
+114.48%
  1. Stock Market
  2. Stocks
  3. EOLS Stock